NCT05875948: An ongoing trial by River 2 Renal Corp.
This trial is ongoing. It must report results 2 weeks, 1 day from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05875948 |
|---|---|
| Title | A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome - Acute Kidney Injury |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2023 |
| Completion date | Dec. 31, 2024 |
| Required reporting date | Dec. 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |